Search

Your search keyword '"Polilli, Ennio"' showing total 242 results

Search Constraints

Start Over You searched for: Author "Polilli, Ennio" Remove constraint Author: "Polilli, Ennio"
242 results on '"Polilli, Ennio"'

Search Results

1. Predictors of bacteremia and death, including immune status, in a large single-center cohort of unvaccinated ICU patients with COVID-19 pneumonia

6. Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections.

7. Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant Acinetobacter baumannii Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients' Prognosis.

10. Systemic Connective Tissue Disease and Neuromyelitis Optica Spectrum Disorder Coexistence: A Systematic Review and Meta-Analysis.

11. Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report

13. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy

17. Prevalence and Predictors of Low Bone Mineral Density and Fragility Fractures Among HIV-Infected Patients at One Italian Center After Universal DXA Screening: Sensitivity and Specificity of Current Guidelines on Bone Mineral Density Management

23. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

24. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

26. Raccomandazioni per la gestione di variabili preanalitiche legate al paziente nella determinazione del PSA in fase di screening e follow-up di cancro prostatico

29. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

30. A SOA Based Solution for MDRO Surveillance and Improved Antibiotic Prescription in the Abruzzo Region

32. Comparison of Monocyte Distribution Width (MDW) and Procalcitonin for early recognition of sepsis

33. Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease

34. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

35. Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study

36. THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance

37. SAT-159-Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma

38. THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience

39. Acupuncture for the treatment of severe acute pain in Herpes Zoster: results of a nested, open-label, randomized trial in the VZV Pain Study

40. Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy

41. Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature

42. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C.

43. First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing

44. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

45. Improvement of ALT decay kinetics by all-oral HCV treatment: role of NS5A inhibitors and differences with IFN-based regimens

47. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study

48. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

50. Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district

Catalog

Books, media, physical & digital resources